SciTech's core technology involves a proprietary intravenous (IV) drug delivery system capable of delivering insoluble (poor bioavailability) anti-cancer agents, such as neutral retinoids and other membrane seeking drugs. The first product utilizing this technology in clinical development will be intravenous fenretinide, an agent first developed by Johnson & Johnson (J&J) that has been proven to be clinically active in a number of difficult to treat cancers.    

It takes the form of a unique lipid nanoparticle that differs from the typical lipid vesicle technology (liposomal technology). In the latter, a drug is traditionally solubilized in the aqueous internal portion of the liposome for controlled drug release and distribution. SciTech’s free flowing drug delivery platform, however, involves the specific incorporation of a water insoluble anti-cancer drug within the lipid bilayer of the vesicle. This design results in the significantly greater delivery of an otherwise insoluble compound. Since the composition of the delivery system is chemically well defined, the potential for adverse effects from exposure to common toxic excipients is minimized. The use of fully defined ingredients also results in better control of stability, shelf life and potency of the drug product. More importantly, this critical breakthrough has led to the creation of a platform technology that has the potential of delivering other compounds that suffer from the same chemical limitations as fenretinide, leading to the treatment of multiple acute, life-threatening conditions.

No known existing product(s) under development carries all these important attributes.